Cho Yoon Young, Kim Bongseong, Jin Sang-Man, Jung Chan-Hee, Mok Ji Oh, Kim Sun Wook, Chung Jae Hoon, Han Kyung-Do, Kim Tae Hyuk
Division of Endocrinology and Metabolism, Department of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
Thyroid. 2025 Jan;35(1):60-68. doi: 10.1089/thy.2024.0270. Epub 2024 Dec 20.
Several meta-analyses have found no association between Graves' disease (GD) and an increased risk of incident diabetes; however, the intricate relationship between thyroid dysfunction and diabetes remains underexplored. In this study, we aimed to evaluate the risk of incident type 2 diabetes (T2DM) in a population newly diagnosed with GD, focusing on different treatment methods and treatment duration. This was a retrospective population-based study utilizing data from the Korean National Health Insurance database. We included 36,243 patients with GD and 36,243 controls, matched with age and sex. We calculated the incidence of T2DM among patients and controls based on treatment methods, such as medical therapy, radioactive iodine therapy (RAIT), and surgery. We examined the cumulative dose and duration of antithyroid drug (ATD) use for each patient. The majority of patients (34,867, 96.2%) were treated with ATDs, followed by RAIT (1093 patients, 3%), and surgery (283 patients, 0.8%). After adjusting for age; sex; income; comorbidities, including hypertension, dyslipidemia, and cancer; body mass index; smoking; drinking; and exercise, patients with GD exhibited a higher risk of developing diabetes (hazard ratio [HR] = 1.13 [95% confidence interval 1.06-1.21]) than controls (5.1% vs. 4.5%, respectively). While the risk was the highest within the first six months after GD diagnosis (HR = 3.21), it was significant between six months and two years (HR = 1.36) and was comparable with the controls two years after GD diagnosis (HR = 0.93). A longer duration of ATD treatment and a higher cumulative dose were associated with an increased risk of diabetes. However, the risks for T2DM did not differ according to treatment modality or clinical outcomes, which was probably related to the small number of patients in each subgroup. Our findings highlight the negative impact of GD on the development of T2DM. Patients newly diagnosed with GD can be considered for diabetes screening to facilitate early detection and intervention.
多项荟萃分析发现,格雷夫斯病(GD)与新发糖尿病风险增加之间无关联;然而,甲状腺功能障碍与糖尿病之间的复杂关系仍未得到充分探索。在本研究中,我们旨在评估新诊断为GD的人群中发生2型糖尿病(T2DM)的风险,重点关注不同的治疗方法和治疗持续时间。这是一项基于人群的回顾性研究,利用了韩国国民健康保险数据库中的数据。我们纳入了36243例GD患者和36243例年龄及性别匹配的对照。我们根据治疗方法,如药物治疗、放射性碘治疗(RAIT)和手术,计算了患者和对照中T2DM的发病率。我们检查了每位患者抗甲状腺药物(ATD)的累积剂量和使用持续时间。大多数患者(34867例,96.2%)接受了ATD治疗,其次是RAIT(1093例,3%)和手术(283例,0.8%)。在调整年龄、性别、收入、合并症(包括高血压、血脂异常和癌症)、体重指数、吸烟、饮酒和运动后,GD患者发生糖尿病的风险高于对照(风险比[HR]=1.13[95%置信区间1.06 - 1.21])(分别为5.1%和4.5%)。虽然风险在GD诊断后的前六个月内最高(HR = 3.21),但在六个月至两年之间显著(HR = 1.36),并且在GD诊断两年后与对照相当(HR = 0.93)。ATD治疗持续时间较长和累积剂量较高与糖尿病风险增加相关。然而,T2DM的风险在不同治疗方式或临床结局方面并无差异,这可能与每个亚组中的患者数量较少有关。我们的研究结果突出了GD对T2DM发生的负面影响。新诊断为GD的患者可考虑进行糖尿病筛查,以促进早期发现和干预。